T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies.
T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies.
复制标题
DOI：
10.1111/bjh.17877
复制
发表时间：
2022-03
影响因子：
6.5
通讯作者：
Corradini P
中科院分区：
文献类型：
--
作者：
Marasco V;Carniti C;Guidetti A;Farina L;Magni M;Miceli R;Calabretta L;Verderio P;Ljevar S;Serpenti F;Morelli D;Apolone G;Ippolito G;Agrati C;Corradini P
受淋巴恶性肿瘤 (LM) 影响的患者通常免疫功能低下，因 COVID-19 导致的死亡率增加。这项前瞻性研究评估了 263 名慢性淋巴细胞白血病、B 细胞和 T 细胞淋巴瘤以及多发性骨髓瘤患者接受完整 mRNA 疫苗接种后的血清学和 T 细胞反应。结果与 167 名年龄和性别相匹配的健康受试者的结果进行了比较。总体而言，患者血清转化率为 64·6%：在疫苗接种前 12 个月内接受抗癌治疗的患者的血清学反应较低：55% vs 81·9% (P < 0·001)。抗 CD20 抗体加化疗治疗与最低的血清转化率相关：17·6% 对比 71·2% (P < 0·001)。在积极治疗的患者亚组中进行的多变量分析中，血清转化的独立预测因素包括：抗 CD20 治疗 (P < 0·001)、侵袭性 B 细胞淋巴瘤诊断 (P = 0·002) 和免疫球蛋白 M 水平 <40 mg/dl (P = 0·030)。对 99 名患者进行了 T 细胞反应评估，并在其中 85 名患者（86%）中检测到了 T 细胞反应。值得注意的是，74% 的血清阴性患者有 T 细胞反应，但 13·1% 的病例没有细胞和体液反应。我们的研究结果引起了人们对 LM 患者（尤其是接受抗 CD20 抗体的患者）可能从疫苗接种中获得保护的担忧。这些患者应严格遵守各项防护措施。
Patients affected by lymphoid malignancies (LM) are frequently immune‐compromised, suffering increased mortality from COVID‐19. This prospective study evaluated serological and T‐cell responses after complete mRNA vaccination in 263 patients affected by chronic lymphocytic leukaemia, B‐ and T‐cell lymphomas and multiple myeloma. Results were compared with those of 167 healthy subjects matched for age and sex. Overall, patient seroconversion rate was 64·6%: serological response was lower in those receiving anti‐cancer treatments in the 12 months before vaccination: 55% vs 81·9% (P < 0·001). Anti‐CD20 antibody plus chemotherapy treatment was associated with the lowest seroconversion rate: 17·6% vs. 71·2% (P < 0·001). In the multivariate analysis conducted in the subgroup of patients on active treatment, independent predictors for seroconversion were: anti‐CD20 treatment (P < 0·001), aggressive B‐cell lymphoma diagnosis (P = 0·002), and immunoglobulin M levels <40 mg/dl (P = 0·030). The T‐cell response was evaluated in 99 patients and detected in 85 of them (86%). Of note, 74% of seronegative patients had a T‐cell response, but both cellular and humoral responses were absent in 13·1% of cases. Our findings raise some concerns about the protection that patients with LM, particularly those receiving anti‐CD20 antibodies, may gain from vaccination. These patients should strictly maintain all the protective measures.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
DOI：
10.1158/1078-0432.ccr-11-1221
发表时间：
2012-03-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Noonan K;Rudraraju L;Ferguson A;Emerling A;Pasetti MF;Huff CA;Borrello I
通讯作者：
Borrello I
DOI：
10.1016/s2352-3026(21)00110-1
发表时间：
2021-06
期刊：
The Lancet. Haematology
影响因子：
--
作者：
Bird S;Panopoulou A;Shea RL;Tsui M;Saso R;Sud A;West S;Smith K;Barwood J;Kaczmarek E;Panlaqui C;Kaiser M;Stern S;Pawlyn C;Boyd K
通讯作者：
Boyd K
影响因子：
4.5
作者：
Agrati C;Castilletti C;Goletti D;Meschi S;Sacchi A;Matusali G;Bordoni V;Petrone L;Lapa D;Notari S;Vanini V;Colavita F;Aiello A;Agresta A;Farroni C;Grassi G;Leone S;Vaia F;Capobianchi MR;Ippolito G;Puro V;On Behalf Of The Inmi Covid-Vaccine Study Group
通讯作者：
On Behalf Of The Inmi Covid-Vaccine Study Group
影响因子：
56.3
作者：
Cordonnier, Catherine;Einarsdottir, Sigrun;Wenneras, Christine
通讯作者：
Wenneras, Christine